Revitope Oncology Signs License Agreement Providing Genmab A/S Access To Revitope's Conditional TCE Technology, TwoGATE; Revitope Oncology To Receive Upfront Payment Of $9M With Milestone And Fee Payments Up To $600M Plus Tiered Single-Digit Royalties...
Revitope Oncology Signs License Agreement Providing Genmab A/S Access To Revitope's Conditional TCE Technology, TwoGATE; Revitope Oncology To Receive Upfront Payment Of $9M With Milestone And Fee Payments Up To $600M Plus Tiered Single-Digit Royalties...
Revitope Oncology Signs License Agreement Providing Genmab A/S Access To Revitope's Conditional TCE Technology, TwoGATE; Revitope Oncology To Receive Upfront Payment Of $9M With Milestone And Fee Payments Up To $600M Plus Tiered Single-Digit Royalties On Sales Of Successfully Commercialized Therapies
Revitope Oncology簽訂許可協議，提供給genmab A/S使用Revitope的條件性TCE Technology，TwoGATE；Revitope Oncology將獲得900萬美元的預付款，同時還將獲得里程碑和費用支付高達60000萬美元，並根據成功商業化的治療產品銷售額支付分階段的單位收入
-
Genmab secures rights to Revitope's proprietary, conditional T Cell Engagement (TCE) TwoGATE technology for conducting research against multiple drug target pairs with options for exclusive worldwide development and commercialization for up to three resulting products
- Revitope to receive an upfront payment of USD $9 million with milestone and fee payments up to USD $600 million plus tiered single-digit royalties on sales of successfully commercialized therapies
- Genmab獲得Revitope專有的、條件性的T細胞結合(TCE) TwoGATE技術的權利，用於針對多種藥物靶點對進行研究，包括獲得最多三種商品化產品的全球獨家開發和商業化期權
- Revitope將收到900萬美元的預付款，同時還將獲得里程碑和費用支付高達60000萬美元，並根據成功商業化的治療產品銷售額支付分階段的單位收入
BOSTON, Oct. 29, 2024 /PRNewswire/ -- Revitope Oncology Inc. (Revitope), a biotechnology company advancing a new class of precision cancer immunotherapies, announced today that it has signed a license agreement providing Genmab A/S (Genmab) access to Revitope's conditional TCE technology, TwoGATE. Genmab is granted exclusive rights to utilize TwoGate for multiple drug target pairs during a multi-year research period, including the option to take up to three exclusive licenses for worldwide development and commercialization of the resulting products.
2024年10月29日，波士頓 / PRNewswire——生物技術公司Revitope Oncology Inc.（Revitope）宣佈今天已簽署許可協議，授予Genmab A/S（Genmab）使用Revitope的條件性TCE Technology，TwoGATE的訪問權。Genmab獲得獨家使用權，可在多年的研究期間利用TwoGate進行多種藥物靶點對，包括獲得最多三項全球開發和商業化的商品化產品的選擇權
TwoGATE leverages the dual antigen binding requirement of a unique split paratope that assembles on the tumor cell surface to potently engage T cells with high precision, potentially addressing key areas of unmet need in the treatment of solid tumors.
TwoGATE利用了腫瘤細胞表面的獨特分裂抗原結合位點的雙抗原結合要求，與高精度地刺激T細胞，有望解決實體腫瘤治療中未滿足需求的關鍵領域
